Verrica Pharmaceuticals (VRCA) Stock Statistics & Valuation Metrics

Verrica Pharmaceuticals has a market cap or net worth of $105.65M. The enterprise value is $29.85M.

Verrica Pharmaceuticals has 17,178,785 shares outstanding. The number of shares has decreased by -2.65% in one year.

Verrica Pharmaceuticals’s return on equity (ROE) is -0.72 and return on invested capital (ROIC) is -37.97%.

The current PE Ratio of Verrica Pharmaceuticals is ―. Verrica Pharmaceuticals’s PEG ratio is 0.06.

In the last 12 months, Verrica Pharmaceuticals had revenue of 35.58M and earned -17.89M in profits. Earnings per share was -1.68.

In the last 12 months, operating cash flow was -17.63M and capital expenditures 0.00, giving a free cash flow of -17.63M billion.

Verrica Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Verrica Pharmaceuticals upcoming earnings date is May 12, 2026, TBA (Confirmed).

Verrica Pharmaceuticals as a current ratio of 2.59, with Debt / Equity ratio of 6.59%

In the past 12 months, Verrica Pharmaceuticals has paid 0.00 in taxes.

Verrica Pharmaceuticals EV to EBITDA ratio is -4.92, with an EV/FCF ratio of -3.40.

Verrica Pharmaceuticals has $30.15M in cash and marketable securities with $1.63M in debt, giving a net cash position of $28.52M billion.

Gross margin is 93.84%, with operating margin of -34.25%, and net profit margin of -50.27%.

The average price target for Verrica Pharmaceuticals is $18.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy